Acute single-dose (500 mg empty stomach, no prior experience): Usually unremarkable — no detectable subjective effect. Bromelain is not a "feel" supplement. The exception is users with active sinus congestion or mild systemic inflammation, who sometimes report modest symptom relief within 2–6 hours of first dose.

3–7 day course post-injury (the canonical MMA use case): Users typically describe faster bruise color progression (red → blue → green → yellow → fade in ~5–7 days instead of 10–14), reduced palpable edema by 48–72 hours post-injury, and less stiffness on day 2–3 post-trauma. The subjective signal is real but modest — comparable to icing + elevation done well, not comparable to oral NSAIDs for acute pain (bromelain has weaker analgesic effect than ibuprofen but better mechanism for tissue clearance).

Chronic use (4–12 weeks daily, anti-inflammatory baseline): Most users describe no obvious daily "feel." Joint stiffness reductions emerge gradually in OA users by week 4–8. In allergic-rhinitis / histamine-sensitive users on the quercetin + bromelain stack, the perceived benefit usually accrues over 2–4 weeks.

Sinus / respiratory application: Onset within hours to a day for users with active rhinosinusitis — congestion clearing, postnasal drip reduction.

Side-effect signal: Mild GI upset in ~5–10% of users (loose stool, transient stomach discomfort) — usually resolves with food or dose reduction; the rare allergic reaction is dramatic (orofacial swelling, hives) and typically appears within 30–90 minutes of first or second dose in pineapple-/latex-sensitive individuals.

Repeat-user trend (community data, n=11): Median 41 days of use. 3 more-positive, 4 neutral, 4 more-negative at follow-up — i.e., a mixed long-term satisfaction signal consistent with the modest-effect-size literature. People who use it PRN for acute indications tend to keep it in the cabinet; people who try it as a daily anti-inflammatory often drop it because the daily "feel" is absent.

• Tolerance does not develop in any clinically meaningful sense. Bromelain works by direct proteolytic + cytokine-modulatory action on circulating mediators — there is no receptor down-regulation pathway analogous to neurotransmitter pharmacology. Long-term users maintain effect.
• Cycling protocol: None required. PRN use is appropriate by design (the canonical use cases are acute injury + sinusitis + seasonal allergies). Daily chronic use for OA / joint inflammation doesn't require cycling — but for cost-effectiveness, 4–8 week trials with reassessment are appropriate, given that the daily anti-inflammatory baseline is better served by omega-3 + curcumin in most archetypes.
• Reset protocol: Not applicable — no dependence pharmacology.
• Cross-tolerance: None. Bromelain does not cross-tolerize with NSAIDs, glucocorticoids, or other anti-inflammatories — the mechanisms are largely independent.

Synergistic stacks (clinically grounded)

• Bromelain + quercetin (the classic stack). Most-combined-with at 85 community mentions. Mechanism: (a) mutual absorption enhancement — community data and mechanistic studies suggest bromelain improves quercetin oral absorption (proteolytic clearance of paracellular protein matrix, possibly enhanced intestinal permeability), with reports of 80–300% higher quercetin AUC when co-administered; (b) complementary anti-inflammatory + antihistamine action — quercetin stabilizes mast cells (antihistamine effect), bromelain reduces bradykinin/cytokine load. Practical pairing: bromelain 500 mg + quercetin 500 mg, BID, empty stomach. This is the highest-confidence stack in this file.
• Bromelain + curcumin (Meriva or other phytosome). Independent anti-inflammatory mechanisms (curcumin: NF-κB + COX-2 + JAK/STAT; bromelain: bradykinin + cytokine + fibrin). Effects appear additive in post-surgical / post-traumatic edema use cases. Practical pairing: bromelain 500 mg TID + Meriva 500 mg BID for 5–7 days post-injury.
• Bromelain + omega-3 (EPA/DHA). Omega-3 provides chronic-baseline anti-inflammatory + resolvin-mediated resolution; bromelain provides acute-event proteolytic action. Mechanistically complementary, not redundant.
• Bromelain + boswellia (5-LOX inhibitor). Multi-pathway anti-inflammatory stack popular in OA. Mechanistically additive (boswellia hits 5-LOX → leukotrienes; bromelain hits NF-κB + bradykinin).
• Bromelain + trypsin + rutoside (Wobenzym / Phlogenzym formulation). The systemic-enzyme therapy combination — EU-popular, with supportive evidence in OA, TMJ-OA, and post-surgical edema (Bhandari 2024 systematic review).

Neutral / safe co-administration

• Vitamin C, vitamin D3, zinc, magnesium, B-complex, multivitamins
• Creatine, beta-alanine, citrulline malate (typical sport-supplement baseline)
• Whey protein / casein — but timing matters: dose bromelain ≥90 min away from the protein meal for systemic effect; co-dose with protein only if you want digestive-enzyme action
• Caffeine, L-theanine — no meaningful interaction
• Probiotics — no interaction
• Adaptogens (rhodiola, ashwagandha) — no interaction

Avoid stacking with

• Anticoagulants: warfarin, DOACs (apixaban, rivaroxaban, dabigatran, edoxaban), heparin, fondaparinux — additive bleeding risk. Theoretical, not always observed clinically, but the precautionary stance is universal.
• Antiplatelet drugs: aspirin (low-dose cardioprotective or higher), clopidogrel, ticagrelor, prasugrel — additive bleeding risk.
• High-dose NSAIDs (ibuprofen, naproxen, diclofenac): additive GI + bleeding risk. Low-dose / occasional NSAID use overlaps acceptably for most users, but chronic high-dose NSAID + bromelain is unwise.
• Other fibrinolytic / antiplatelet supplements at high dose: nattokinase, serrapeptase, high-dose fish oil (>3 g/day with anticoagulant), high-dose vitamin E (>800 IU/day), garlic extract — additive bleeding tendency.
• Pre/post-surgery window (2 weeks each side): discontinue.

• CYP450 interactions: Negligible. Bromelain does not appear to meaningfully inhibit or induce major CYPs (CYP3A4, 2D6, 2C9, 2C19, 1A2). Not a significant source of drug-drug PK interactions.
• Antibiotic absorption enhancement: Old (1970s–80s) literature reports bromelain enhances oral absorption of amoxicillin, tetracycline, and other antibiotics — proposed mechanism: increased intestinal permeability + direct effect on mucus barrier. Clinically still discussed in sinusitis treatment (bromelain + antibiotic). Not a contraindication; mostly an enhancement.
• Anticoagulants / antiplatelets: Covered above — pharmacodynamic interaction (additive bleeding risk), not pharmacokinetic.
• Chemotherapy: Bromelain has been studied as a chemo-adjunct (in-vitro and small clinical studies suggest possible additive cytotoxicity with 5-FU, doxorubicin in some tumor models). Outside the scope of this archetype but flag for any user on active oncology treatment — discuss with oncologist.
• Renal / hepatic dose adjustment: Not formally established. Mild caution in severe impairment. Not a concern in this archetype.

• No actionable PGx markers for bromelain response or adverse-event risk as of 2026. Bromelain is a polyclonal enzyme mixture acting on extracellular targets — there is no narrow receptor pharmacology to PGx-stratify.
• CYP2C9 / VKORC1 variants (warfarin sensitivity): not directly relevant for bromelain but relevant for the interaction risk in warfarin users — slow-metabolizer warfarin patients have less safety margin for additive bromelain bleeding effects.
• HLA allergic-reaction susceptibility: No PGx data specific to pineapple/latex cross-reactivity; clinical history (known pineapple allergy, latex-fruit syndrome) remains the only meaningful prediction tool.
• For Dylan (23andMe results expected June 2026): No bromelain-specific genotype findings to act on. Standard caveats apply (CYP2C9 + VKORC1 if any future anticoagulant prescribed; allergy clinical history). Verdict does not change with any plausible PGx outcome.

Sourcing-difficulty rating: Easy. Available at any vitamin shop, Amazon, iHerb, and most pharmacies. The skill is reading the GDU label correctly — pick 2,000+ GDU/g for systemic anti-inflammatory use; lower GDU products are fine for digestive-enzyme indications only. No regulatory or legal sourcing constraints in the US, EU, or Canada for the oral supplement form.

Cost: A 60-day supply of 500 mg TID dosing (90 caps × $0.20 each) = **$18 for a typical post-injury course**. Daily 1,000 mg cost: ~$10–15/month.

• For acute injury / post-spar use (PRN): Mostly subjective — bruise resolution timeline, palpable edema, pain at injury site, range-of-motion recovery. No labs warranted.
• For chronic anti-inflammatory daily use (e.g., 4–12 week OA trial):
  • hs-CRP at baseline and 8 weeks. A modest reduction is expected if bromelain is contributing; failure to budge after 8 weeks at adequate dose argues for discontinuation.
  • IL-6 (when accessible) — same logic; bromelain's IL-6 suppression is mechanistically central but the assay is less commonly accessible in routine bloodwork.
  • Fibrinogen — modest reduction is plausible given fibrinolytic mechanism; useful corroboration.
  • CBC + platelet count + PT/aPTT — annually at minimum if using chronically, especially if any concurrent anticoagulant or antiplatelet pressure (e.g., heavy fish oil, vitamin E).
  • LFTs (ALT/AST) — annually; rare case-reported transaminase elevations at very high chronic doses.
• For Dylan's planned June 2026 bloodwork: No specific bromelain-related biomarker pattern to look for unless he initiates a chronic daily course. PRN use does not warrant lab tracking.